





APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/430,966	11/01/1999	BART DE CORTE	JAB-1425	8053
75	590 08/06/2002			
ADULEY A CIAMPORCERO JR			EXAMINER	
JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 089337003			BALASUBRAMANIAN, VENKATARAMAN	
			ART UNIT	PAPER NUMBER
			1624	٨
			DATE MAILED: 08/06/2002	\propto 0

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		09/430,966	DE CORTE ET AL.			
		Examiner	Art Unit			
		Venkataraman Balasubramanian	1624			
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status 1)⊠	Responsive to communication(s) filed on 14 M	May 2002				
2a)⊠						
3)	This action is FINAL . 2b) This action is non-final. Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4)🖂	Claim(s) 8,10 and 19-21 is/are pending in the	application.				
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5)	Claim(s) is/are allowed.					
6)⊠	☑ Claim(s) <u>8,10 and 19-21</u> is/are rejected.					
7)	Claim(s) is/are objected to.					
· ·	Claim(s) are subject to restriction and/or	r election requirement.				
	ion Papers					
,	The specification is objected to by the Examine					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. ☐ Certified copies of the priority documents have been received.						
	Certified copies of the priority documents have been received in Application No					
Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
 a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 						
Attachment(s)						
2) Notic	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal P	(PTO-413) Paper No(s) Patent Application (PTO-152)			

Application/Control Number: 09/430,966

Art Unit: 1624

DETAILED ACTION

Applicants' response filed on 5/14/2002 is made of record.

Claims 8, 10, and 19-21 are pending.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 8, 10 and 19-21 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-4 of U.S. Patent No. 6,197,719 for reasons of record.

Applicants' argument to overcome this rejection made in the previous office action is not persuasive.

Applicants argue that a) while instant claims all variable groups (L, Y, Q and – NR⁵-phenyl or pyridyl) attached to the pyrimidine ring are in fixed position, in the US patent 6,107,719, all the substituents except R⁵ are permitted to float and b) that Y of instant claim which corresponds to R⁵ of the said patent, embrace various substituents

Application/Control Number: 09/430,966

Art Unit: 1624

besides hydrogen and C₁-C₄ alkyl taught in R⁵ of the said patent. Hence one would not be motivated to make instant compounds and use for the HIV treatment.

Contrary to applicants' urging there is clear-cut equivalency teaching. By floating the substituents, the reference teaches equivalency of all the position with those exemplified positions as seen in examples and tables shown on col. 19 through 37 for the same utility namely for treating HIV. The fact that the instant Y is large scope than R⁵ of the said patent does not make those compounds bearing R⁵ as hydrogen and C₁-C₄ alkyl to patentably distinct as these compounds are also included in the instant claims. Thus one trained in the art would be a motivated make compound taught by the reference including those differing in the position of the substituents and expect the compounds thus made to possess the same utility in view of the equivalency teaching.

The double patenting rejection is proper and is maintained.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Application/Control Number: 09/430,966

Art Unit: 1624

Page 4

Any inquiry concerning this communication from the examiner should be

addressed to Venkataraman Balasubramanian (Bala) whose telephone number is (703)

305-1674. The examiner can normally be reached on Monday through Thursday from

8.00 AM to 6.00 PM. The Supervisory Patent Examiner (SPE) of the art unit 1624 is

Mukund Shah whose telephone number is (703) 308-4716.

The fax phone number for the organization where this application or proceeding is

assigned (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to the receptionist whose telephone number is (703) 308-

1235.

V. Balasubramanian

VENKATARAMAN BALASUBRAMANIAN PATENT EXAMINER

7/31/2002.